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Abstract Arterial hypertension in childhood is less fre-
quent as compared to adulthood but is more likely to be
secondary to an underlying disorder. After ruling out more
obvious causes, some patients still present with strongly
suspected secondary hypertension of yet unknown etiology.
A number of these children have hypertension due to single
gene mutations inherited in an autosomal dominant or
recessive fashion. The finding of abnormal potassium levels
(low or high) in the presence of suppressed renin secretion,
and metabolic alkalosis or acidosis should prompt consid-
eration of these familial diseases. However, mild hyperten-
sion and the absence of electrolyte abnormalities do not
exclude hereditary conditions. In monogenic hypertensive
disorders, three distinct mechanisms leading to the common
final pathway of increased sodium reabsorption, volume
expansion, and low plasma renin activity are documented.
The first mechanism relates to gain-of-function mutations
with a subsequent hyperactivity of renal sodium and
chloride reabsorption leading to plasma volume expansion
(e.g., Liddle's syndrome, Gordon's syndrome). The second
mechanism involves deficiencies of enzymes that regulate
adrenal steroid hormone synthesis and deactivation (e.g.,
subtypes of congenital adrenal hyperplasia, apparent min-
eralocorticoid excess (AME)). The third mechanism is
characterized by excessive aldosterone synthesis that
escapes normal regulatory mechanisms and leading to
volume-dependent hypertension in the presence of sup-
pressed renin release (glucocorticoid remediable aldoste-
ronism). Hormonal studies coupled with genetic testing can
help in the early diagnosis of these disorders.
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Introduction
Arterial hypertension in childhood is less frequent as
compared to adulthood but is more likely to be secondary
to an underlying disorder. Essential hypertension is rarely
diagnosed in children less than 5 years of age and only
more often beyond the age of 10 years. Obviously, it is of
paramount importance to identify secondary origins of
persistent hypertension (blood pressure >95th percentile for
height and gender) in these children [14]. Treatment of
hypertension without a specified workup such as often seen
in the adult setting is not justified.
The assessment of a hypertensive child should begin
with a careful personal and family medical history and a
physical examination. If not diagnostic, investigations
should focus on renal or cardiac causes. Appropriate
investigations include: full blood cell count, electrolytes
with emphasis on potassium, acid–base balance, uric acid
and creatinine, urinalysis, and the measurement of the ratio
of urinary protein to creatinine in an early morning urine
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sample [10]. The trans-tubular potassium gradient, an
estimate of aldosterone bioactivity, is useful with respect
to diseases with extracellular fluid volume expansion
secondary to increased mineralocorticoid activity. Renin
and aldosterone should be measured and normal values in
children are available [11]. Renal imaging by ultrasound
and Doppler of renal arteries is essential. Further imaging
techniques such as NMR, angiography, or renal scan are
performed if appropriate. Echocardiography has a place in
the workup in every child with severe hypertension in order
to assess left ventricular mass and to rule out aortic
coarctation [10].
Having excluded the more obvious causes, there are still
patients in whom secondary hypertension is strongly
suspected while the standard search for an etiology is
unsuccessful. A number of these children will have
hypertension due to single gene mutation inherited in an
autosomal dominant or recessive fashion. These familial
disorders are common enough to be included in the
differential diagnosis of any hypertensive child irrespective
of the severity. The purpose of this review is to discuss the
monogenic forms of low-renin hypertension, which may
become manifest in childhood. Of particular importance,
we will point out when and how should the pediatrician
search for these diseases and discuss the appropriate
antihypertensive strategies. Further causes of monogenic
hypertension will only shortly be addressed (Table 1).
When to consider a monogenic form of hypertension
The inheritance pattern of a given family may already
indicate the presence of a monogenic form of hypertension.
A family history of severe hypertension, especially with
early onset (adolescence or young adult age) is suggestive
of one of the dominantly inherited conditions, whereas
consanguinity may indicate recessive inheritance. Never-
theless, family history is often misleading as essential
hypertension is highly prevalent in adults. Consideration of
hereditary forms of hypertension should not be limited to
children with severe hypertension or electrolyte abnormal-
ities, since mild hypertension and the absence of electrolyte
abnormalities does not exclude an inherited condition; in
fact, many individuals with these forms of inherited
hypertension have only mild to moderate hypertension
without electrolyte disturbances. Abnormal potassium
levels (low or high), suppressed renin, and metabolic
alkalosis or acidosis should rise suspicion for the presence
of these familial disorders. Plasma renin activity or renin
concentration (random) and plasma aldosterone levels are
useful at the beginning (prior to therapy) to identify the
etiology of the hypertension. All hereditary forms of
hypertension lead to a suppression of the renin–angiotensin
system (low plasma renin level or reduced plasma renin
activity) due to an autonomous plasma volume expansion.
In addition to hyporeninemia, expansion of the extracellular
fluid volume can be associated with hypouricemia (by
reducing its proximal tubular reabsorption). In synopsis
with the suppressed renin, the level of aldosterone
(increased or suppressed) will further discriminate the
different diseases (Table 2).
Physiology of Na transport in the distal nephron
The consequence of a defective gene in each case of these
forms of hypertension is abnormally increased sodium (Na)
Table 1 Some characteristic physical examination findings in
childhood hypertension, which might suggest the existence of an
underlying monogenic disease
Finding Possible underlying monogenic
disease
Café-au-lait-spots, axillary or
groin freckling, Lisch's nodules
(=iris hamartomas)
Neurofibromatosis type 1
Hypomelanotic macules, facial
angiofibroma, shagreen patch
Tuberous sclerosis complex
(Bourneville's disease)
Short metacarpala bones (length of
phalanges often normal), short
(or low normal) stature
Autosomal-dominant
hypertension with
brachydactyly (Bilginturan's
disease)
Palpable kidneys Polycystic kidney disease
Girl with webbed neck, widely
spaced nipples, short 4th
metacarpal bone, short stature,
swollen hands and feet (neonatal
age)
Turner's syndrome
Icteric liver disease, heart murmur
(pulmonary stenosis), ocular
abnormalities (embryotoxon),
short stature, facial dysmorphy
Alagille's arteriohepatic dysplasia
Upturned nose, depressed nasal
bridge, periorbital fullness,
broad mouth, and full lips
(=elfin face), short stature,
cardiac murmur
Williams–Beuren's syndrome
Episodic headache or pallor,
sweating, tachycardia
Pheochromocytoma or
paragangliomab
Ambiguous genitalia, virilization Congenital adrenal hyperplasia
(11β-hydroxylase deficiency or
17α-hydroxylase deficiency)
Muscles weakness Hereditary diseases that cause
hypertension and hypokalemia
(low-renin hypertension)
a Especially 4th and 5th metacarpal bones
b In childhood pheochromocytoma and paraganglioma often occur in
the context of a genetic disorder (multiple endocrine neoplasia type
2A or 2B, von Hippel–Lindau disease, neurofibromatosis type 1,
succinate dehydrogenase mutations)
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transport in the distal nephron causing an expansion of the
circulating plasma volume and a consecutive increase of the
cardiac output with resulting hypertension. A compromised
renal natriuresis favoring a positive Na and thus volume
balance in the distal nephron is an essential element of
forms of hypertension associated with a high cardiac
output, as hypothesized by Guyton et al. [7]. Therefore,
we will discuss distal nephron Na transport as related to the
different diseases presented in this review.
The distal convoluted tubule cell and the principal cells
of the collecting duct cell are the two cell types most
important for Na transport in the distal nephron. A
simplified model of these cell types is presented in Fig. 1.
The target of the regulation is the transepithelial Na
transport into the cell through the luminal Na transporter:
in the distal convoluted tubule cell, it is the thiazide-
sensitive sodium chloride (NaCl) cotransporter (NCC); in
the collecting duct, it is the amiloride-sensitive epithelial Na
Table 2 Findings in inherited forms of hypertension
Inheritance
pattern
Age K Renin Aldo Aldo/
Renin
Diagnostic indicators Therapy
AME AR I,C,A ↓ (N) ↓ ↓ Urinary cortisol metabolites ↑, Urinary cortisone metabolites ↓ Spironolactone
Eplerenone
Hypertension ameliorates with mineralocorticoid receptor
antagonists
Amiloride
(Thiazide if
hypercalciuria)
GRA AD I,C ↓ or
N
↓ ↑ (N) ↑ Urinary 18-oxotetrahydrocortisol and
18-hydroxycortisol/tetrahydroaldosterone ratio ↑
Glucocorticoids
Amiloride
Hypertension ameliorates with glucocorticoids
and mineralocorticoid receptor antagonists
Triamterene
CAH AR I ↓ or
N
↓ ↓ Ambiguous genitalia/amenorrhea, virilization/precocious puberty Spironolactone
Hypertension ameliorates with mineralocorticoid receptor
antagonists
Eplerenone
Liddle AD C,A ↓ or
N
↓ ↓ Family history Amiloride
Hypertension does not ameliorate with mineralocorticoid receptor
antagonists
Triamterene
Gordon AD A,
(C)
↑ or
N
↓ ↑ or
N
(↑) Family history Low-dose thiazide
Hypertension does not ameliorate with mineralocorticoid receptor
antagonists
AME Apparent mineralocorticoid excess, GRA glucocorticoid remediable aldosteronism, CAH congenital adrenal hyperplasia, AD autosomal
dominant, AR autosomal recessive, Age typical age at presentation, I infancy, C childhood, A adulthood, K potassium, N normal, ↓ decreased, ↑
increased, Aldo aldosterone, Aldo/Renin ratio of aldosterone to renin
Na+ EpithelialNa+ Channel
11 HSD-2
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Cl-
Na+-Cl-
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Fig. 1 Simplified diagram of a
distal nephron sodium transporting
cell in the distal convolute tubule
and collecting duct. The amiloride-
sensitive epithelial Na channel
(ENaC) is found predominantly in
principal cells of the collecting
duct and the thiazide-sensitive
sodium chloride cotransporter
(NCC) in the distal convolute
tubule. 11βHSD-2 11β-
hydroxysteroid dehydrogenase
type 2 enzyme, WNK1 and
WNK4 kinases with no lysine
serine/threonine protein kinase
type 1 and 4, respectively, Na/K-
ATPase contraluminal sodium-
potassium adenosine triphosphate.
Activation is indicated by green
arrows and suppression by red
lines ending with a circle (adapted
from Vehaskari [20])
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channel (ENaC). Additionally, basolateral sodium–potassi-
um adenosine triphosphate (Na/K-ATPase) and the luminal
renal outer medulla K channel (ROMK) are responsible for
Na and K homeostasis. The mechanisms of regulation are
still insufficiently understood, the best documented mech-
anism being the regulation by mineralocorticoids. Aldoste-
rone binds to the cytosolic mineralocorticoid receptor (MR)
and leads to increased activity of the apical Na transporter
(ENaC). Deoxycorticosterone and deoxycortisol and their
metabolites are alternative agonists of the MR with cortisol
being the most important one. The 11β-hydroxysteroid
dehydrogenase type 2 enzyme (11βHSD-2) which converts
active cortisol to the inactive cortisone protects the MR
from cortisol, an alternative agonist of the MR, thus
establishing the aldosterone specificity of the MR [3].
Na reabsorption is controlled by mineralocorticoid active
steroid hormones in both the distal convoluted tubule and
the collecting duct. Additional regulatory elements are
involved including, but not limited to kinases (WNK1 and
WNK4) [22]. WNK4 exerts a suppression of the NCC
activity. WNK1 inhibits WNK4 and activates ENaC.
Given the magnitude of regulatory mechanisms, multiple
candidate genes might be involved in abnormalities of the
Na transport and consecutive hypertension. The known
disorders leading to hypertension can be classified in (a)
induced by a mineralocorticoid effect (with the disorder
being primarily in the distal nephron or being primarily
adrenal disorder) and (b) induced by excessive natrium
uptake independent of mineralocorticoid action.
How to diagnose a monogenic form of hypertension
The evaluation of the renin–angiotensin–aldosterin system
(RAAS) is of paramount importance for the initial
evaluation of children with a suspected monogenic form
of arterial hypertension. As already discussed, the assess-
ment of the plasma renin activity (or renin concentration)
together with plasma aldosterone concentration is a useful
screening. All these monogenic forms of hypertension share
a low-renin activity (“low-renin hypertension”), whereas
suppressed plasma aldosterone is present in all forms of
inherited hypertension except primary aldosteronism
(which in most cases is not heritable and is not a matter
of discussion in this review), glucorticoid remediable
aldosteronism, and Gordon's syndrome (Table 2; Fig. 2,
and next chapter). Electrolyte abnormalities like metabolic
alkalosis with hypokalemia or metabolic acidosis with
hyperkalemia are important markers for the first suspicion
of these forms of monogenic hypertension but may be
absent in many individuals with hereditary forms of
hypertension. In some hypokalemic patients with low-
renin hypertension, mechanical trauma during venipuncture
results in the release of potassium from red cells and causes
apparently normal or even high levels of potassium.
The next step for the evaluation of distal tubular
functions, especially the function of the ENaC and
mineralocorticoid activity, is the assessment of the trans-
tubular potassium gradient (TTKG), which is high (>2)
despite hypokalemia with increased ENaC activity. The
TTKG is derived from (potassiumurine*osmolarityplasma)/
(potassiumplasma*osmolarityurine).
Urinary steroid hormone profiling (in a 24-h urine
specimen) is another important step for the evaluation of
the different forms of hereditary hypertension. The analysis
of the steroid hormone metabolites and the respective
apparent enzyme activities in the urine provides informa-
tion on the adrenal production and metabolism of gluco-
corticoids, mineralocorticoids, and sexual hormones, thus
assisting in locating the putative defect. Genetic testing for
the mutations causing hereditary hypertension is increas-
ingly becoming available. Most tests are based on direct
DNA sequencing or on probing for known mutations. It
must be noted that the test spectrum provided is variable
and while most tests will only consider known mutants,
some might also include the gene as a whole.
Pathophysiology of diseases, diagnosis, and treatment
In the following section, we aim to list the most common
heritable diseases with a clinical phenotype to be observed
as early as in childhood or during adolescence. Diagnostic
procedures and treatment options of these different diseases
are briefly explained. The flow chart on Fig. 2 aids to
discriminate between the different diseases described. Other
hereditary conditions causing arterial hypertension such as
neurofibromatosis type I, tuberous sclerosis, Turner's
syndrome, familial pheochromocytoma, polycystic kidney
disease, autosomal-dominant hypertension with brachydac-
tyly, and Williams–Beuren syndrome are beyond the scope
of this review and are briefly described in Table 1.
Hypertension induced by a mineralocorticoid effect
Syndrome of apparent mineralocorticoid excess
This is a rare autosomal recessive disorder due to an
inactivating mutation of the 11β-hydroxysteroid dehydro-
genase (HSD) type 2 enzyme [21]. As a result, cortisol can
bind to the MR (Fig. 1). Hypokalemia with metabolic
alkalosis is observed. Renal concentrating defect (due to the
hypokalemia) and hypercalciuria with nephrocalcinosis
may be present [13]. The severe phenotype begins in early
childhood with low birth weight and failure to thrive in the
presence of severe arterial hypertension, leading very early
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to end organ damage [1]. Milder phenotypes have been
described without electrolyte abnormalities and develop-
ment of arterial hypertension only in adulthood [13, 15].
The diagnosis should be suspected in any form of low-
renin, low aldosterone hypertension with signs of mineral-
ocorticoid excess, like an increased trans-tubular potassium
gradient (TTKG). Urinary steroid hormone profiling can
confirm the diagnosis showing a low apparent enzyme
activity as given by an increased ratio of (tetrahydrocortisol
+ allotetrahydrocortisol)/tetrahydrocortisone or free corti-
sol/free cortisone in a 24-h urine sample. Genetic testing is
available. The genetic disease must be well distinguished
from liquorice abusus which inhibits the 11β-HSD type 2
enzyme and may cause a similar picture with low-renin
arterial hypertension with hypokalemia.
The therapy consists of MR antagonists and ENaC blockers
like spironolacotone or eplerenone and amiloride, respectively,
as well as symptomatic K supplementation and dietary Na
restricition. Thiazide diuretics may ameliorate hypercalciuria.
Glucocorticoid remediable aldosteronism (familial
hyperaldosteronism type I)
The gene for the aldosterone synthase (CYP11B2 expressed
in the zona glomerulosa) is considered to be the result of an
ancient duplication of the gene of the cortisol and
corticosterone synthezising enzyme 11β-hydroxylase
(CYP11B1 expressed in the zona fasciculata of the adrenal
cortex) closely neighbored on chromosome 8. Glucocorti-
coid remediable aldosteronism (GRA) is the result of
unequal crossing over between these two genes [8]. As a
result, the hybrid gene has the CYP11B1-specific ACTH-
responsive promoter and an aldosterone synthase coding
region, resulting in ACTH-stimulated aldosterone produc-
tion, mainly independent of renin. The high levels of
mineralocorticoids activate the MR and upregulate Na
reabsorption and K secretion.
The hereditary pattern is autosomal dominant and is
absent in blacks. Most individuals have severe hypertension
Fig. 2 Flow chart for the discrimination of different heritable forms of arterial hypertension. Non-heritable forms of hypertension and primary
aldosteronism (Conn's syndrome) are not discussed. K potassium, N normal
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since infancy but milder phenotypes have been described
[2]. GRA patients are at risk for cerebral aneurysms and
intracranial bleeding, therefore, magnetic resonance screen-
ing beginning at puberty has been recommended [9, 20].
Mild hypokalemia and metabolic alkalosis can be observed.
Plasma renin activity is always suppressed, yet plasma
aldosterone concentration may be normal. An increased
ratio of aldosterone to renin is highly suggestive of the
differential diagnosis of primary aldosteronism. The genetic
testing for the chimeric gene has eliminated the need for
complicated evaluations like dexamethasone suppression
test, adrenal imaging, and adrenal-vein sampling, yet we
suggest to perform a urinary steroid hormone analysis to
establish the biochemical features of the disease before
testing genetics [20]. Therapy of first choice therapy is
represented by glucocorticoids in order to suppress ACTH
and the resulting ACTH-stimulated mineralocorticoid pro-
duction [19]. MR antagonists can be added.
Congenital adrenal hyperplasia—subtypes associated
with arterial hypertension
The most common type of congenital adrenal hyperplasia
(CAH), i.e., the 21-hydroxylase deficiency, causes a Na-
losing state and does not cause hypertension. Deoxycortisol,
deoxycorticosterone, and typical as well as atypical metabo-
lites express mineralocorticoid activity. In two subtypes of
CAH, there is an accumulation of intermediate products with
MR activity. Defects in 11β-hydroxylase (CAH type IV) and
17α-hydroxylase (CAH type V) lead to an overproduction of
21-hydroxylated steroids, which are responsible for the
activation of the MR. In type IV CAH, the enzyme block
results in an increased sex hormone with androgenic action,
causing virilization in girls and precocious puberty in boys. In
type V CAH, the inability to synthesize cortisol and the early
block in sex hormone synthesis results in primary amenorrhea
and delayed sexual development in girls, whereas boys
have ambiguous genitalia [12]. In both forms, aldosterone
synthesis is greatly reduced. Steroid profile analysis leads
to the diagnosis. Treatment is based on steroid supple-
mentation in type IV and both steroids and sex hormones
in type V disease. Hypertension can be improved with MR
antagonists.
Hypertension induced by excessive renal tubular sodium
uptake independent of mineralocorticoid action
Liddle's syndrome
Liddle's syndrome is characterized by an increased ENaC-
mediated Na reabsorption in the distal tubule, due to gain-
of-function mutations of the encoding gene [17]. Like most
activating mutations not affecting reproduction capabilities
and gestational outcome, Liddle's syndrome has an autoso-
mal dominant inheritance pattern. Early-onset hypertension
with hypokalemia, metabolic alkalosis, and sometimes
hypercalciuria are the clinical characteristics of the disease
[4]. Plasma renin activity and plasma aldosterone levels are
markedly suppressed. Liddle's syndrome may be the most
common type of monogenic hypertension, and it has been
described in many different populations (Caucasians,
Asians, and Blacks). The treatment consists of a low-salt
diet and substances that directly inhibit ENaC, like
amiloride or triamterene. MR antagonists are without effect
(which can be used as diagnostic tool to suspect the
disease). Of interest, loss-of-function mutations have also
been described, causing water and salt wasting and
consequently hyperaldosteronism (pseudohypoaldosteron-
ism type I).
Gordon's syndrome (familial hyperkalemic hypertension,
pseudohypoaldosteronism type II)
The characteristics of Gordon's syndrome are hyperkalemia
with normal renal function, mild hyperchloremic metabolic
acidosis, low urinary excretion of sodium, hypercalciuria,
and hypertension [5, 6].
The syndrome has been linked to abnormal function
of the thiazide sensitive nephron segment, the distal
convolute tubule. Mutations in the kinases WNK1 and
WNK4 have been identified to be responsible for some
forms of Gordon's syndrome [22]. As no activating
mutations have been found in the NCC, the genetic
background of other forms of Gordon's syndrome remains
unclear. Gordon's syndrome is inherited as an autosomal
dominant trait. The metabolic abnormalities may precede
the development of arterial hypertension (Spitzer–Weinstein
syndrome with hyperkalemia, metabolic acidosis, and
growth failure is now believed to be early presentation
of Gordon's syndrome [18]). Plasma renin activity is
suppressed together with normal or high aldosterone
levels. In fact, despite the volume overload, aldosterone
is not always suppressed because hyperkalemia can induce
its secretion.
The therapy consists of low-dose thiazide diuretics.
Pathophysiologically, the clinical features of Gordon's
syndrome are the opposite of Gitelman syndrome, charac-
terized by abnormalities in the NCC [16].
Conclusion
Hypertension in children frequently develop as a result of
RAAS activation secondary to renal disease but occasion-
ally is because of salt and water overload due to abnormal
electrolyte transport. In monogenic hypertensive disorders,
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three distinct mechanisms leading to the common final
pathway of increased sodium reabsorption, volume expan-
sion, and low plasma renin activity are documented:
1. Mutations with consequent hyperactivity of sodium and
chloride transporters leading to hypertension (e.g.,
Liddle's syndrome, Gordon's syndrome).
2. Deficiencies of enzyme that regulate adrenal steroid
metabolism and activity (e.g., CAH, AME).
3. Excessive aldosterone synthesis that escapes normal
regulatory mechanisms and gives volume-dependent
hypertension and suppresses renin release (GRA).
In conclusion, the key points of this review can be
summarized, as follows:
1. All monogenic forms of hypertension lead to volume
expansion.
2. All monogenic forms of hypertension are associated
with low-renin activity (low-renin hypertension).
3. Arterial hypertension with electrolyte disturbances is
highly suggestive for monogenic forms of hypertension.
4. To evaluate distal tubular dysfunction (especially the
function of the ENaC and mineralocorticoid activity),
assess the TTKG, its formula is (potassiumurine*osmolar-
ityplasma)/(potassiumplasma*osmolarityurine). TTKG is
high (>2) despite hypokalemia with increased ENaC or
mineralocorticoid activity.
5. Urinary steroid hormone analysis and genetic testing are
additional tools in the early diagnosis of these disorders.
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